Cargando…
Luteal Phase in Assisted Reproductive Technology
Luteal phase (LP) is the period of time beginning shortly after ovulation and ending either with luteolysis, shortly before menstrual bleeding, or with the establishment of pregnancy. During the LP, the corpus luteum (CL) secretes progesterone and some other hormones that are essential to prepare th...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580649/ https://www.ncbi.nlm.nih.gov/pubmed/36304702 http://dx.doi.org/10.3389/frph.2020.595183 |
_version_ | 1784812435249561600 |
---|---|
author | Tesarik, Jan Conde-López, Cristina Galán-Lázaro, Maribel Mendoza-Tesarik, Raquel |
author_facet | Tesarik, Jan Conde-López, Cristina Galán-Lázaro, Maribel Mendoza-Tesarik, Raquel |
author_sort | Tesarik, Jan |
collection | PubMed |
description | Luteal phase (LP) is the period of time beginning shortly after ovulation and ending either with luteolysis, shortly before menstrual bleeding, or with the establishment of pregnancy. During the LP, the corpus luteum (CL) secretes progesterone and some other hormones that are essential to prepare the uterus for implantation and further development of the embryo, the function known as uterine receptivity. LP deficiency (LPD) can occur when the secretory activity of the CL is deficient, but also in cases of normal CL function, where it is caused by a defective endometrial response to normal levels of progesterone. LPD is particularly frequent in treatments using assisted reproductive technology (ART). Controlled ovarian stimulation usually aims to obtain the highest number possible of good-quality oocytes and requires the use of gonadotropin-releasing hormone (GnRH) analogs, to prevent premature ovulation, as well as an ovulation trigger to achieve timed final oocyte maturation. Altogether, these treatments suppress pituitary secretion of luteinizing hormone (LH), required for the formation and early activity of the CL. In addition to problems of endometrial receptivity for embryos, LPD also leads to dysfunction of the local uterine immune system, with an increased risk of embryo rejection, abnormally high uterine contractility, and restriction of uterine blood flow. There are two alternatives of LPD prevention: a direct administration of exogenous progesterone to restore the physiological progesterone serum concentration independently of the CL function, on the one hand, and treatments aimed to stimulate the CL activity so as to increase endogenous progesterone production, on the other hand. In case of pregnancy, some kind of LP support is often needed until the luteal–placental shift occurs. If LPD is caused by defective response of the endometrium and uterine immune cells to normal concentrations of progesterone, a still poorly defined condition, symptomatic treatments are the only available solution currently available. |
format | Online Article Text |
id | pubmed-9580649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95806492022-10-26 Luteal Phase in Assisted Reproductive Technology Tesarik, Jan Conde-López, Cristina Galán-Lázaro, Maribel Mendoza-Tesarik, Raquel Front Reprod Health Reproductive Health Luteal phase (LP) is the period of time beginning shortly after ovulation and ending either with luteolysis, shortly before menstrual bleeding, or with the establishment of pregnancy. During the LP, the corpus luteum (CL) secretes progesterone and some other hormones that are essential to prepare the uterus for implantation and further development of the embryo, the function known as uterine receptivity. LP deficiency (LPD) can occur when the secretory activity of the CL is deficient, but also in cases of normal CL function, where it is caused by a defective endometrial response to normal levels of progesterone. LPD is particularly frequent in treatments using assisted reproductive technology (ART). Controlled ovarian stimulation usually aims to obtain the highest number possible of good-quality oocytes and requires the use of gonadotropin-releasing hormone (GnRH) analogs, to prevent premature ovulation, as well as an ovulation trigger to achieve timed final oocyte maturation. Altogether, these treatments suppress pituitary secretion of luteinizing hormone (LH), required for the formation and early activity of the CL. In addition to problems of endometrial receptivity for embryos, LPD also leads to dysfunction of the local uterine immune system, with an increased risk of embryo rejection, abnormally high uterine contractility, and restriction of uterine blood flow. There are two alternatives of LPD prevention: a direct administration of exogenous progesterone to restore the physiological progesterone serum concentration independently of the CL function, on the one hand, and treatments aimed to stimulate the CL activity so as to increase endogenous progesterone production, on the other hand. In case of pregnancy, some kind of LP support is often needed until the luteal–placental shift occurs. If LPD is caused by defective response of the endometrium and uterine immune cells to normal concentrations of progesterone, a still poorly defined condition, symptomatic treatments are the only available solution currently available. Frontiers Media S.A. 2020-12-07 /pmc/articles/PMC9580649/ /pubmed/36304702 http://dx.doi.org/10.3389/frph.2020.595183 Text en Copyright © 2020 Tesarik, Conde-López, Galán-Lázaro and Mendoza-Tesarik. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Reproductive Health Tesarik, Jan Conde-López, Cristina Galán-Lázaro, Maribel Mendoza-Tesarik, Raquel Luteal Phase in Assisted Reproductive Technology |
title | Luteal Phase in Assisted Reproductive Technology |
title_full | Luteal Phase in Assisted Reproductive Technology |
title_fullStr | Luteal Phase in Assisted Reproductive Technology |
title_full_unstemmed | Luteal Phase in Assisted Reproductive Technology |
title_short | Luteal Phase in Assisted Reproductive Technology |
title_sort | luteal phase in assisted reproductive technology |
topic | Reproductive Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580649/ https://www.ncbi.nlm.nih.gov/pubmed/36304702 http://dx.doi.org/10.3389/frph.2020.595183 |
work_keys_str_mv | AT tesarikjan lutealphaseinassistedreproductivetechnology AT condelopezcristina lutealphaseinassistedreproductivetechnology AT galanlazaromaribel lutealphaseinassistedreproductivetechnology AT mendozatesarikraquel lutealphaseinassistedreproductivetechnology |